Japan Medical Device Technology

What Japan Medical Device Technology does

Japan Medical Device Technology Co., Ltd. (株式会社 日本医療機器技研, JMDT) is a Kumamoto-based, privately held medical device R&D company that was reorganized from SEAM Chemical Research Institute in October 2014 and became a wholly-owned subsidiary of Kaneka Corporation (株式会社カネカ) in November 2023. The company specializes in the application of bioresorbable (生体吸収性) materials to high-function medical devices, with its core technical focus being the research and development of coronary stents (冠動脈ステント) used to treat cardiovascular conditions. Beyond its core stent program, JMDT provides commissioned contract development services (受託開発) for other medical devices, operating a B2B professional services model rather than a direct product-sales model.

JMDT's technology base is centered on proprietary bioresorbable material science, a specialized materials domain where the ability to engineer polymer-based implants that safely dissolve in the body is technically demanding and carries long development cycles. The company is anchored by a comprehensive partnership signed in September 2015 with Kumamoto Prefecture, Kumamoto University, and Fujilight Metal Co., Ltd., which provides academic research collaboration and talent access. Its headquarters sits in the Kumamoto New Business Support Facility D Building in Mashiki Town, Kumamoto Prefecture, and registered capital is 10 million yen.

The business model is a captive R&D services model: JMDT generates revenue primarily through commissioned research and development work rather than commercial product sales, with its parent Kaneka Corporation acting as the principal (and likely sole material) client. Pricing is not publicly disclosed and is negotiated on a project-by-project basis. The company employs between 11 and 50 staff and has no disclosed external venture funding or public listing. CEO 鈴木 和雄 (Suzuki Kazuo) leads the organization.

Name

Japan Medical Device Technology

Legal name

株式会社 日本医療機器技研

Website

https://jmdt.co.jp

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Japan Medical Device Technology is a Kumamoto-based medical device R&D subsidiary of Kaneka Corporation, specializing in bioresorbable materials applied to coronary stents and other medical device contract development.

Ownership category

akta.pro rank

Product category

Medical Device Contract R&D

NAICS

Surgical and Medical Instrument Manufacturing (339112), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

akta.pro secondary industries

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ), Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL)

Keywords

• Bioresorbable medical devices
• Coronary stent development
• Contract medical device R&D
• Absorbable polymer implants
• Cardiovascular device research

Headquarters

HQ city

Kumamoto

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain

Revenue model

1. Contract Development Services (受託開発): The company conducts commissioned R&D for medical devices on behalf of clients, likely including its parent company Kaneka Corporation. This is a B2B service model focused on research and development rather than product sales.

Core offering

JMDT researches and develops medical devices built from bioresorbable (absorbable) materials, with a flagship coronary stent program intended to dissolve in the body after supporting the vessel. In parallel, the company offers contract medical device development services, applying its bioresorbable materials expertise and regulatory R&D capabilities to programs for partner firms.

Product overview

Japan Medical Device Technology (日本医療機器技研) operates as a single-product medical device company specializing in the research and development of bioresorbable material-based coronary stents. The company also provides contract development services for other medical devices. Founded in October 2014 and wholly owned by Kaneka Corporation since November 2023, the company leverages advanced expertise and cutting-edge technology to create high-functionality medical devices that contribute to regional economy and society.

Differentiator

Problem solved

Functional benefit

Products and services

• Bioresorbable Coronary Stent Development

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core.

• Japan's AMED (Agency for Medical Research and Development)coreStrategic or Co-development Partner · 7 May 2026India-Japan bilateral cooperation: AMED signed Memorandum of Cooperation with India's ICMR and DST on health and medical devices during bilateral meeting in New Delhi (May 2026). Covers medical research collaboration in medical devices.
• Kumamoto PrefecturecoreStrategic or Co-development PartnerComprehensive partnership agreement signed in September 2015 with Kumamoto Prefecture, Kumamoto University, and Fujilight Metal Co., Ltd. This partnership led to the establishment of JMDT's Kumamoto office and provides collaborative research ecosystem.
• Kumamoto UniversitycoreStrategic or Co-development PartnerComprehensive partnership agreement signed in September 2015. Provides academic collaboration, research talent, and university partnership for medical device R&D activities.
• Fujilight Metal Co., Ltd. (不二ライトメタル株式会社)coreStrategic or Co-development PartnerComprehensive partnership agreement signed in September 2015 with Kumamoto Prefecture, Kumamoto University, and Fujilight Metal Co., Ltd. for collaborative medical device research and development.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Elixir Medical: Developer of the DESolve bioresorbable coronary scaffold and other novel cardiovascular devices. Comparable specialty cardiovascular device developer with bioresorbable scaffold technology targeting the same end market.
• Meril Life Sciences: India-headquartered medical device company developing the MeRes100 bioresorbable coronary scaffold. Directly comparable bioresorbable stent program and an emerging-market counterparty to JMDT for the AMED India-Japan partnership.
• Kyoto Medical Planning: Japan-based developer of bioresorbable and novel coronary stent platforms. Closely comparable to JMDT in geography, scale, and product category, with overlapping R&D focus on absorbable cardiovascular scaffolds.

Broad incumbents

• Boston Scientific: Major coronary stent manufacturer (Promus, Synergy) with deep clinical and hospital relationships. Represents the entrenched DES incumbent whose installed base JMDT's bioresorbable platform must compete against.
• Abbott Vascular: Global leader in coronary stents (Xience DES) and previously the Absorb bioresorbable scaffold. Defines the competitive benchmark for bioresorbable stent development and serves as the dominant incumbent JMDT's technology would have to displace or differentiate from.
• Medtronic: Global medical device giant with the Resolute and Onyx coronary DES families and broad cardiovascular portfolio. Comparable as the third major incumbent setting the standard for next-generation coronary stent commercialization.

Emerging players

• REVA Medical: Pre-commercial developer of bioresorbable polymer-based coronary scaffolds (Fantom). Small specialty player with overlapping bioresorbable scaffold technology and similar commercialization-stage challenges to JMDT.
• Arterius Limited: UK-based developer of bioresorbable polymer scaffolds for vascular applications. Comparable emerging-stage R&D player in absorbable cardiovascular devices, illustrating the broader competitive set JMDT will encounter.

Others

• Kaneka Corporation: Parent company and 100% owner of JMDT; major Japanese chemicals and materials manufacturer with medical device operations including bioresorbable polymers. Relevant as the corporate acquirer and commercialization channel rather than a competitor.

Regional players

• Lifetech Scientific: China-headquartered developer and manufacturer of cardiovascular interventional devices including structural heart and peripheral products. Comparable Asia-based cardiovascular device developer operating in a neighboring geography to JMDT.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Japan Medical Device Technology